R&D Strengths
An internationally competitive platform for precision drug target deconvolution and drug screening.
Genome library screening
Target deconvolution concept
Architecture concept for screening base
Core therapeutic directions
Our Team
22222
1111111
Product Pipeline & Key News
Driven by a dual-engine strategy of technology transfer from our parent company and external License-in agreements, Anku Biology has achieved significant milestones in recent years.
2022
Innovative Therapies for ALS & Fibrosis
Anku Biology signed an exclusive License-in agreement with Germany-based Neurovision Pharma GmbH. We have secured the development and commercialization rights for the Greater China region for their proprietary antisense oligonucleotide (ASO) candidate drug targeting TGFBRII.
2022-2023
Glioblastoma Therapy Rights
Through a licensing agreement with our parent company, Austria-based JLP Health, Anku Biology obtained exclusive development and commercialization rights in China for an innovative Glioblastoma therapy. All core research data and IP rights have been transferred.
2021
Industry-Academia Collaboration
The Anku Biology technical team visited top-tier academic institutions, including the Kunming Institute of Botany at the Chinese Academy of Sciences, to explore leveraging our target analysis platform for the modernization of natural products.
Contact US
Angal Biotechnology Co., Ltd. was established in Suzhou in 2019, jointly founded by JLP Health GmbH of Vienna, Jiangsu Industrial Technology Research Institute, and Suzhou New District Hi-Tech Industrial Co., Ltd.As an innovative global biotech company, we are committed to developing first-class drugs and benefiting human health.
Telephone:
Email: